Physician profile
Karla D Cabrera
NPI 1932191434
$2,117.00
in general payments reported to CMS, 2019-2025
13 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $526 · 2023: $236 · 2024: $632 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,247.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $349.82 | 2021-2024 | |
| Corcept Therapeutics | $155.71 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $86.48 | 2021-2022 | |
| Dexcom, INC. | $55.21 | 2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $38.97 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals Lp | $36.34 | 2022-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $35.70 | 2021 | |
| Lilly USA, LLC | $33.87 | 2021 | |
| Abbott Laboratories | $28.71 | 2024 | Diamondback Peripheral |
| Abbvie INC. | $25.76 | 2025 | |
| Xeris Pharmaceuticals, INC. | $11.74 | 2021 | |
| Cranial Technologies, INC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.